摘要
目的:自从1993年SchmidtWolf建立细胞因子诱导的杀伤细胞(CIK)制备方法以来,CIK/IL-2在净化骨髓和治疗血液病方面取得较多经验,但缺乏CIK/IL-2治疗实体瘤的临床资料。本文总结应用CIK/IL-2治疗41例实体瘤的临床经验,分析肿瘤负荷对该疗法临床疗效的影响。方法:选择无临床病灶的高危复发患者和存在明显临床病灶的晚期实体瘤患者,分离外周血单个核细胞,制备CIK。CIK联合IL-2静脉输注患者。结果:高危复发组中,姑息性治疗9例,根治性治疗14例,中位随访时间13个月。接受CIK/IL-2治疗后姑息性治疗者复发6例,根治性治疗者复发3例,复发率分别为66.7%和21.4%(P<0.05)。此外,CIK/IL-2治疗常规治疗失败的晚期实体瘤患者18例,4例稳定。结论:CIK/IL-2的临床疗效受肿瘤负荷制约,接受CIK/IL-2辅助治疗前应联合其它治疗方法尽量降低肿瘤负荷。
Objective： Since the protocol of cytokine-induced killer （CIK） was established by Schmidt Wolf in 1993, the CIK therapy has been mainly used in purge of marrow and treatment of leukemia rather than solid tumors. This study intends to summarize the clinical outcome of 41 patients with solid tumor who received CIK/IL-2 therapy, trying to analyze the role of tumor load in the CIK/IL-2 therapy. Methods： The patients with high-risk recurrence and of advanced stage were recruited. CIK was prepared from autologous PBMCs. CIK combined n-2 was intravenously injected to the patients. Results： During the follow-up from 3 months to 24 months, recurrence occurred in 6 of the 9 cases who subjected to palliative resection. However, recurrence occurred in only 3 of the 14 cases undergoing the radical resection. So the recurrence rate was 66.7% and 21.4% respectively （P〈0.05）. In addition, of the 18 cases with advanced tumor stable patient＇s condition occurred in 4 cases. Conclusion：The efficacy of CIK/IL-2 therapy is correlated with tumor load. To improve the outcome of CIK/IL-2 therapy it is recommended to reduce tumor load as far as possible before this treatment.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第15期847-848,855,共3页
Chinese Journal of Clinical Oncology
基金
广东省科技攻关项目基金资助(编号:2002C30314)
